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Mo lec u lar  tar geted  can cer  ther apy  is  a  prom is ing  treat ment  strat egy.  Con sid er ing  the  cen tral
role of the epi  der  mal growth fac  tor re  cep  tor in cell pro  lif  er  a  tion and sur  vival, there are in  di  -
ca  tions that tar  geted agents like ty  ro  sine kinase in  hib  i  tors, i. e., erlotinib, may en  hance the
antitumor treat ment by ra di a tion. The aim of this study is to an a lyze the in ac ti va tion ef fects of 
g-rays and to test the radiosensitizing po  ten  tial of erlotinib on hu  man lung adenocarcinoma
cells in vi  tro. Ir  ra  di  a  tions were per  formed with doses rang  ing from 1 Gy to 8 Gy. In or  der to
in  crease the radiosensitivity of CRL-5876 lung adenocarcinoma cells, the cells were treated
with a clin  i  cally rel  e  vant con  cen  tra  tion of 2 µM erlotinib. The ef  fects of sin  gle and com  bined
treat ments  were mon i tored  us ing  clonogenic  sur vival,  cell  vi a bil ity and  pro lif er a tion as says at
dif  fer  ent time points. For the de  tec  tion and vi  su  al  iza  tion of the phosphorylated histone
H2AX (g-H2AX), an im  por  tant bi  o  log  i  cal marker of DNA dou  ble-strand break for  ma  tion,
flu o res cence immunocytochemistry, was per formed. The re sponse to the treat ment was mon -
i  tored at four time points: 30 min, 2, 6, and 24 h. Ir  ra  di  a  tions with g-rays re  sulted in sig  nif  i  -
cant  cell  in ac ti va tion  re gard ing  all  an a lyzed  bi o log i cal  end points.  Com bined  treat ments  re -
vealed  con sis tent  cell  in ac ti va tion.  More over,  com pared  to  g-rays alone, el  e  vated lev  els of
g-H2AX foci were ob  served af  ter pre  treat  ment with erlotinib, in  di  cat  ing radiosensitization
through im  paired DNA re  pair.
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IN TRO DUC TION
Lung can  cer is the most fre  quent cause of can  cer
mor  tal  ity world  wide [1]. This ag  gres  sive dis  ease can be
sub  di  vided as small-cell lung car  ci  noma (SCLC) and
non-small-cell lung car  ci  noma (NSCLC) [2]. Within
NSCLC, rep  re  sent  ing the ma  jor  ity of lung can  cer cases,
adenocarcinoma is the most fre  quently en  coun  tered his  -
tol  ogy [3]. The stag  ing of lung can  cer is es  sen  tial for de  -
ter min ing the ap pro pri ate ther a peu tic ap proach. Sur gi cal
in  ter  ven  tion is the most com  mon treat  ment for early
stage NSCLC. When di ag nosed close to 70% of pa tients
are al  ready in the ad  vanced stage of the dis  ease [4]. Ra  -
dio ther apy  and  che mo ther apy,  alone  or  com bined,  re -
main the most com  mon op  tion for these pa  tients [5].
Can  cer cells are less ef  fec  tive in re  pair  ing the ra  di  a  -
tion-in  duced dam  age than nor  mal cells, mak  ing them
eas ier to be de stroyed if ra di a tion ther apy is ap plied [6].
In re  cent years, new gen  er  a  tions of drugs, i. e.,
tar geted ther a peu tics were de vel oped in or der to block
spe cific  sig nal ing  path ways  in volved  in  can cer  pro -
gres sion [7]. Cer tain mem bers of the fam ily of the epi -
der  mal growth fac  tor re  cep  tor (EGFR) genes have
been overexpressed or oth  er  wise de  reg  u  lated in al  -
most  all  ep i the lial  tu mors,  in clud ing  NSCLC.  This
alone, as well as the find ings on the im por tance of pro -
tein phosphorylation and the dis  cov  ery that the first
onco  gene v-Src is a pro  tein kinase, re  sulted in se  lect  -
ing EGFR as the pri  mary tar  get of mo  lec  u  lar tar  geted
ther apy  [8-10].
EGFR, a mem  ber of the ErbB fam  ily of re  cep  tor
ty  ro  sine kin  ases, is a transmembrane glycoprotein con  -
sist ing of a sin gle polypeptide chain and is found in ma -
jor  ity of nor  mal cells. The intracellular re  gion of the
EGFR is in charge of pro  tein ty  ro  sine kinase ac  tiv  ity
and plays an im por tant role in the reg u la tion of cell pro -
lif er a tion.  EGFR  fam ily  mem bers  are  de reg u lated  in
can cers  by  the  fol low ing  three  mech a nisms:  ac ti va tion
of gene mu ta tions, in creased num ber of gene cop ies (by
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Overexpression of EGFR is found in 40% to 80% of pa -
tients with NSCLC. It is as  so  ci  ated with poor prog  no  -
sis, since it also plays a spe cific role in the pro lif er a tion,
in va sion  and  me tas ta sis  of  ma lig nant  cells  [8,  12].
Most  tar geted  ther a pies  in clude  anti-EGFR
monoclonal  an ti bod ies  and  small-mol e cule  ty ro sine
kinase  in hib i tors  (TKI)  [13].  Erlotinib  hy dro chlo ride
(Tarceva®) is a quinazoline small-mol  e  cule in  hib  i  tor
of the EGFR. It is an ac tive and well-tol er ated agent in
ad  vanced NSCLC [14]. Erlotinib is ap  proved for the
treat  ment of pa  tients with lo  cally ad  vanced or met  a  -
static NSCLC af ter fail ure of at least one prior che mo -
ther apy  reg i men  [15].
Ra di a tion  in duces  the  ex pres sion  of  EGFR  in
can cer  cells,  pos si bly  con trib ut ing  to  the  re sis tance  of
those cells to ther  apy [16, 17]. Overexpression of
EGFR by tu  mors is also as  so  ci  ated with re  duced lo  cal
con trol af ter ra di a tion [18]. Block ade of EGFR sig nal -
ling in vi tro has been proven to sen si tize cells to the ef -
fects of ra  di  a  tion [16]. Con  sid  er  ing the new in  sights
into the role of EGFR in DNA re  pair, there is sub  stan  -
tial  in ter est  in  us ing  EGFR  in hib i tors  for  sen si tiz ing
tu mours  to  ra dio ther apy  [17].
Sev eral  stud ies  have  ana lysed  the  com bi na tion
of erlotinib with ra dio ther apy [16, 19, 20]. Clin i cal re -
ports of NSCLC pa  tients with brain me  tas  ta  sis ex  -
posed to whole-brain ra  di  a  tion ther  apy with a par  al  lel
ad min is tra tion  of  erlotinib  dem on strate lon ger  over all
sur vival  with  par tic u lar  ben e fits  marked  for  pa tients
with EGFR mu  ta  tions. The rate of these mu  ta  tions in
the ana  lysed group was much higher than ex  pected
[20]. 
Un der stand ing cel lu lar events and path ways un -
der ly ing the en hance ment of the ra di a tion re sponse by
EGFR in hi bi tion is im por tant for fur ther im prove ment 
of can  cer treat  ment strat  egy. There  fore, in this in vi tro
study, g-rays and erlotinib were com  bined in or  der to
test the radiosensitising po  ten  tial of erlotinib and, at
the same time, im  prove anticancer ef  fects. Combined
ef  fects of these agents were fol  lowed on the
CRL-5876 hu  man NSCLC lung adenocarcinoma
cells.  The  cho sen  bi o log i cal  end points  were:
clonogenic  sur vival,  cell  vi a bil ity  and  pro lif er a tion.
The  level  of ra di a tion sen si tiv ity  is  al most ex clu sively
as  sessed using clonogenic as  say (CA) con  sid  ered as
the gold stan  dard. Colorimetric vi  a  bil  ity as  says, such
as sulforhodamine B (SRB) or 5-bromo-2'-
deoxyuridine (BrdU) test are ba si cally used for the  as -
sess  ment of cel  lu  lar chemosensitivity. These tests are
re  lated to the to  tal cell num  ber or the cor  re  spond  ing
pro lif er a tion  ca pac ity  of  the  cells,  while  the
clonogenic as  say mea  sures the sur  vival of col  o  nies
[21]. All of the men tioned as says were spe cif i cally se -
lected  to  sup port  the  com par i son  of  cell  in ac ti va tion
ef fects pro duced by es sen tially dif fer ent agents: ra di a -
tion by g-rays and radiosensitization via erlotinib.
Phosphorylation of histone H2AX (g-H2AX) was
used for the de  tec  tion of DNA dou  ble-strand breaks
in duced by ion iz ing ra di a tion and was eval u ated at dif -
fer  ent time points. This ki  netic study en  abled the de  -
tec tion of re sid ual DNA dam age at the level of in di vid -
ual cells. The re  la  tion  ship be  tween the loss of
clonogenic abil  ity and the  re  ten  tion of g-H2AX foci
holds for drugs that dam age DNA by dif fer  ent mech  a  -
nisms  [22].  Com bin ing  these  ex per i men tal  meth ods,
ad  di  tional data for the de  sign of new ther  a  peu  tic ap  -
proaches will be ob  tained.
MA TE RIAL  AND  METH ODS
Cell cul  ture
Hu  man NSCLC CRL-5876 cells were pur  -
chased from the Amer  i  can Type Cul  ture Col  lec  tion
(ATCC, Manassas, Va, USA) and were cul  tured in the
RPMI 1640 me  dium (Sigma-Aldrich Chemie GmbH,
Steinheim, Ger  many) sup  ple  mented with 10% foe  tal
calf se rum (FCS) (Sigma-Aldrich Chemie GmbH) and 
pen i cil lin/strep to my cin  (Sigma-Aldrich  Chemie
GmbH). Cells were main  tained in a hu  mid  i  fied at  mo  -
sphere of 5% CO2 at 37 °C (Heraeus, Hanau, Ger  -
many).
Ir ra di a tion  pro ce dure  and
erlotinib  prep a ra tion
CRL-5876 cells were ex  posed to g-rays and/or
erlotinib in the ex  po  nen  tial phase of growth. Ir  ra  di  a  -
tions with 60Co g-rays were per formed at the Vin~a In -
sti  tute of Nu  clear Sci  ences, Bel  grade, Ser  bia. The de  -
liv ered  sin gle  doses  were  in  the  range  from  1 Gy to
8 Gy at the dose rate of ~1 Gy/min. For the as sess ment
of g-H2AX foci, cells were ir  ra  di  ated with a dose of
0.1 Gy at the same dose rate. All cell ir ra di a tions were
per  formed at room tem  per  a  ture, ex  cept for the
immunocytochemistry  pro ce dure  in volv ing  ir ra di a -
tions per  formed at ~0 ºC. Erlotinib (Tarceva®) was
pur chased  from  Roche  Di ag nos tics  GmbH,
Mannheim, Ger  many. The 10 mM stock so  lu  tion was
ob tained  by  dis so lu tion  in  dimethylsulphoside
(DMSO;  SERVA  Elec tro pho re sis  GmbH,  Hei del berg,
Ger  many). That stock so  lu  tion was then se  ri  ally di  -
luted in a cell cul  ture me  dium. Con  sid  er  ing that 2 µM
of  erlotinib  cor re spond  to  clin i cally  rel e vant  doses,
this con  cen  tra  tion was cho  sen for the anal  y  sis of sin  -
gle and com  bined treat  ments with g-rays. The fi  nal
con cen tra tion of DMSO in cell sam ples did not ex ceed 
0.1%. In ac  cor  dance with data cited in lit  er  a  ture, the
drug was ad min is tered 1 h prior to ra di a tion and main -
tained  through out  the  ex per i ment  [23].
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CA was per  formed ac  cord  ing to the pre  vi  ously
de  scribed pro  to  col [24, 25]. Cells were har  vested im  -
me di ately  af ter  ir ra di a tion  and/or  erlotinib  pre treat -
ment and seeded at a suit  able num  ber in trip  li  cate, in
6-well plates. A 7 day time point was cho  sen for the
eval  u  a  tion of radiobiological ef  fects, since it en  ables
at  least  six  dou bling  times  fol low ing  ir ra di a tion  [26].
Af ter the in cu ba tion pe riod of 7 days, cells were rinsed
care fully with phos phate- buf fered sa line (PBS), fixed
with meth a nol (Zorka Pharma, Šabac, Ser bia), stained
with 0.5% Crys tal Vi o let (Al lied Chem i cal, New York, 
USA) in 25% meth a nol for 10 min. Af ter that, the crys -
tal vi  o  let was re  moved, dishes were rinsed with tap
wa  ter and left to dry at room tem  per  a  ture. Col  o  nies
con  sist  ing of 50 or more cells were counted un  der the
in  verted mi  cro  scope. The sur  vival frac  tion of treated
cells was de ter mined by com par ing the num ber of col -
o  nies in treated sam  ples with those in con  trol. Dig  i  tal
im ages from 6-well plates were taken and col ony sizes
mea  sured us  ing ImageJ soft  ware [27].
Cell  vi a bil ity  as say
The Sulforhodamine B (SRB) as  say was used
for cell den  sity de  ter  mi  na  tion [28]. In or  der to check
the re  sults ob  tained by the clonogenic as  say, these re  -
sults were com pared with SRB data [21]. To de fine the
ex per i men tal  con di tions  in  the  SRB  as say,  ex po nen -
tially grow  ing cells were treated with 2 µM erlotinib
for 24, 48, and 72 h. The most pro  nounced sin  gle ef  -
fect of erlotinib was ob  tained at the 72 h time point.
There  fore, vi  a  bil  ity tests were per  formed 72 h and 7
days af  ter the treat  ment of CRL-5876 cells.  The SRB
as  say is based on the mea  sure  ment of the cel  lu  lar pro  -
tein con  tent. The solubilized dye, SRB, binds to the
ba  sic amino ac  ids of cel  lu  lar pro  teins. The colorime-
tric mea  sure  ment of the bound dye pro  vides data on
the to  tal pro  tein con  tent that is cor  re  lated with the cell
num  ber. Cells were seeded in 96-well plates at a den  -
sity of 1000 cells per well and treated in the ex  po  nen  -
tial phase of growth. Af  ter  wards, cho  sen in  cu  ba  tion
pe  riod cells were fixed with 10% trichloroacetic acid
and stained with 0.4% SRB (Sigma-Aldrich Chemie
GmbH) for 15 min. The ex  cess dye was re  moved by
wash  ing with 1% ace  tic acid. The pro  tein-bound dye
was dis  solved in a 10 mM Tris base so  lu  tion for
absorbance de  ter  mi  na  tion, at 550 nm, us  ing a
microplate reader (Wallac, VICTOR2 1420 Multilabel 
coun  ter, Turku, Fin  land).
Cell  pro lif er a tion  as say
The 5-bromo-2'-deoxyuridine (BrdU) as  say
(Roche Di  ag  nos  tics GmbH) was used to mea  sure cell
pro lif er a tion by quan ti fy ing BrdU that is in cor po rated
into the newly syn  the  sized DNA of rep  li  cat  ing cells.
The as  say was per  formed ac  cord  ing to the man  u  fac  -
turer's in  struc  tions and at the same time points as the
SRB as  say (72 h and 7 days af ter treat  ment). The cells
were in  cu  bated with the BrdU la  bel  ing so  lu  tion for 2
h, fixed and in  cu  bated with the anti-BrdU-POD an  ti  -
body. Af  ter re  mov  ing the an  ti  body, the sub  strate so  lu  -
tion was added and in  cu  bated un  til the dye was de  vel  -
oped (from 5 to 30 min). The re  ac  tion was stopped by
add ing the 1M H2SO4 so lu tion. Absorbance was mea -
sured us  ing a microplate reader (Wallac, VICTOR2
1420 Multilabel coun  ter) at a test wave  length of 450
nm.
Immunofluorescence stain  ing
for  de tec tion  of  g-H2AX foci
For the de  tec  tion of g-H2AX, the pri  mary (di  -
rect) immunofluorescence pro  ce  dure was used.
Briefly, cells were grown on glass cover slips in 6-well
dishes, over  night, in or  der to at  tach to the sur  face. At
0.5, 2, 6, and 24 h posttreatment, the me dium was as pi -
rated and cells washed with cold PBS.  The cells were
then  fixed  with ice-cold ac  e  tone-meth  a  nol (1:1) for
30 min at –20 ºC. Fol  low  ing fix  a  tion, the cells were
washed again with PBS and blocked with a 5% bo vine
se  rum al  bu  min (BSA, Frac  tion V; Sigma-Aldrich
Chemie GmbH) in PBS for 1 h at room tem  per  a  ture.
They were then in  cu  bated over  night at 4 ºC with pri  -
mary Alexa Fluor® 488 anti-H2AX Phosphorilated
(Ser 139) an  ti  body (BioLegend, San Diego, Cal.,
USA) at 1:500 di  lu  tion. Af  ter in  cu  ba  tion, the cells 
were  washed  5  times,  each for 10 min, with PBS 
Tween  20  (PBST)  and  counter  stained  with  DAPI
(4',   6-diamidino-2-phenylindole   dihydrochlo-  ride,
1 µg/ml; Sigma-Aldrich Chemie GmbH) in PBS. Fol  -
low  ing ex  ten  sive wash  ing in PBST, cover slips were
mounted on glass slides with the Mowiol® 4-88
antifade mount  ing me  dium (Sigma-Aldrich Chemie
GmbH). Slides were then sealed and ex am ined us ing a
con fo cal la ser scan ning mi cro scope, Leica TCS SP5 II 
(Leica Mi  cro  sys  tems CMS GmbH, Wetzlar, Ger  -
many) and LAS AF Lite soft  ware (Leica Mi  cro  sys  -
tems CMS GmbH). The im  ages were pro  cessed and
the num  ber of g-H2AX foci was de  ter  mined us  ing
CellProfiler im  age anal  y  sis soft  ware. Cells with more
than 10 foci were con  sid  ered as foci-pos  i  tive. In each
ex  per  i  ment, at least 50 foci-pos  i  tive cells were ex  am  -
ined.
Sta tis ti cal  anal y sis
Dur ing  each  ex per i ment,  mea sure ments  were
made in trip  li  cate and each ex  per  i  ment re  peated three
times. The sta tis ti cal anal y sis was per formed us ing in -
de pend ent  Stu dent's  t-test and the value of p < 0.05
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pre  sented as the mean ± SEM (Stan  dard Er  ror of the
Mean).
RE SULTS
Sur  vival of CRL-5876 cells
af  ter erlotinib and g-rays
Clonogenic sur  vival is the con  ven  tion  ally used
cri  te  rion that il  lus  trates the level of cel  lu  lar
radiosensitivity. The sur  vival of CRL-5876 cells was
an a lyzed  af ter their  ex po sure  only  to g-rays, as well as
af  ter their com  bined ex  po  sure to erlotinib and g-rays.
Ex per i men tal  data  were  fit ted  us ing  the  lin ear-qua -
dratic equa  tion: S = exp(–aD – bD2), where S is the
sur viv ing frac tion for dose D, while a and b are the fit -
ting  pa ram e ters.
The best fit curves of the data points for two ex  -
per i men tal set ups ob tained by clonogenic as say 7 days 
af  ter ir  ra  di  a  tion are pre  sented in fig. 1(a), while the
cor re spond ing radiobiological data are given in tab. 1.
These re  sults in  di  cate a rather high level of
radioresistance of the an  a  lyzed cells to lower doses of
g-rays (1 and 2 Gy). The es  ti  mated sur  vival frac  tion at
2 Gy (SF2) is 0.61. Start ing from 4 Gy, the re sponse of
CRL-5876 cells to g-rays is ma jor, show ing sig nif i cant 
cell  in ac ti va tion,  fig.  1(a).  Pre treat ment  of  the  ir ra di -
ated CRL-5876 cells with erlotinib causes higher in hi -
bi tion of cell sur vival with re spect to ir ra di a tion alone.
The   rel a tive  bi o log i cal  ef fec tive ness  at  2  Gy  (RBE
(2 Gy, g)) is 3.12. It is de  fined as the ra  tio of a 2 Gy
g-ray dose and a g-ray dose boosted by erlotinib that
pro duces the same in ac ti va tion level as that given by 2
Gy of the ref er  ence g-rays. More  over, the re  duc  tion in
col ony num ber is ac com pa nied by the re duc tion in col -
ony size, as il lus trated in fig. 1(b). An other com monly
used radiobiological pa  ram  e  ter is the D10 value which
rep re sents  the  ra di a tion  dose  re quired  to  re duce  sur -
vival to 10%. Pre  treat  ment with erlotinib leads to a
drop of D10 from 5.6 ± 0.6 to 2.9 ± 0.4. The
radiosensitization po  ten  tial of erlotinib is also il  lus  -
trated  by  the  sen si ti za tion  en hance ment  ra tio  (SER)
[29]. It is de  fined as the ra  tio of D10 with  out the
sensitizer and D10 with the sensitizer, i. e., in this case,
erlotinib. The ob  tained SER of 1.9 in  di  cates that the
in crease  of  sen si tiv ity  to  g-ir ra di a tion  is  in duced  by
erlotinib (tab. 1). 
Vi a bil ity  and  pro lif er a tion  of
CRL-5876 cells af  ter erlotinib and g-rays
The SRB as say was per formed to as sess cell vi a -
bil ity  af ter  ir ra di a tion  with out  and  with  erlotinib  pre -
treat ment. Ac cord ing to the data ob tained, 72 h af ter ir -
ra di a tion  a  ma jor  dose-de pend ent  re sponse  to  sin gle
g-rays with re spect to the con trol is ob served, fig. 2(a).
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Fig  ure 1. (a) Dose-de  pend  ent sur  vival curves of hu  man
CRL-5876  cells  af ter  ir ra di a tion  with  g-rays and af  ter
com  bined treat  ment with erlotinib and g-rays, ob  tained
by clonogenic as  say. The curves rep  re  sent the best fit of
the sur  vival data to the lin  ear-qua  dratic equa  tion.
Ir  ra  di  a  tion doses are 1, 2, 4, 6, and 8 Gy. Con  cen  tra  tion
of erlotinib is 2 µM. Data ob  tained from 3 ex  per  i  ments
are pre  sented as mean ± SEM; (b) Rel  a  tive re  duc  tion of
the CRL-5876 col  ony size af  ter sin  gle and com  bined
treat  ment with 2 Gy g-rays and 2 µM erlotinibVi  a  bil  ity is re  duced for more than 50%. Both sin  gle
and  com bined  treat ments  show  a  sta tis ti cally  sig nif i -
cant in hi bi tion of cell vi a bil ity com pared to the con trol 
cells (p < 0.001). CRL-5876 cells re  veal a con  sid  er  -
ably  higher  dose-de pend ent  in ac ti va tion  to  com bined
treat ment, as com pared to sin gle treat ment with g-rays. 
At higher doses of ra  di  a  tion, a slightly less pro  -
nounced ef  fect of erlotinib is no  ticed (p < 0.001).
Erlotinib alone also de  creases the vi  a  bil  ity of the cells
72  h  af ter  ad min is tra tion  (p < 0.01), fig. 2(a).
At 7 days of posttreatment with g-rays, higher ir -
ra  di  a  tion doses of 6 Gy and 8 Gy pro  voke a strong de  -
cline in cell vi  a  bil  ity. A better dose-de  pend  ent re  -
sponse with com  bined treat  ment is ob  served when
com pared to the 72 h time point. More over, at this time
point,  vi a bil ity  af ter  com bined  treat ments  is  sig nif i -
cantly dif  fer  ent with re  spect to each sin  gle treat  ment
(p < 0.001 and p < 0.01 com  pared to g-rays and
erlotinib, re  spec  tively), fig. 2(b).
Ac  cord  ing to the re  sults ob  tained by the BrdU
as  say, 72 h af  ter ex  po  sure to sin  gle g-rays, cell pro  lif  -
er a tion de creases from 86% to 4% of the con trol value. 
Com  bined treat  ments pro  voke an even stron  ger and
sta tis ti cally  sig nif i cant  in hi bi tion  of  pro lif er a tion,  not
ex  ceed  ing 10% of the con  trol value, fig. 3(a). Nev  er  -
the less, at the 7 days' time point, cells in di cate pro lif er -
a  tion  re  cov  ery for all treat  ments, as com  pared to the
72 h time point, fig. 3(b).
Ki net ics  of  g-H2AX foci for  ma  tion
In or  der to eval  u  ate the ef  fect of erlotinib pre  -
treat ment  on  ir ra di a tion-in duced  DNA  dam age,
immunofluorescent stain ing of phosphorylated H2AX 
and con fo cal im age anal y ses were per formed 0.5, 2, 6,
and 24 h af ter ir ra di a tion. Rep re sen ta tive mi cro graphs
of the cells con  tain  ing g-H2AX foci are shown in fig.
4(a).  Im me di ately  af ter  ex po sure  to  0.1  Gy  g-rays, the
num ber  of  g-H2AX foci in  creases and af  ter reach  ing
the max  i mum at 2 h, grad u ally de creases as the con se -
quence of DNA re  pair. At 24 h postiradiation, the
num  ber of foci de  creases to the con  trol level. Al  -
though the in duc tion and ki net ics of the dis ap pear ance 
of g-H2AX foci is sim  i  lar in erlotinib pretreated cells,
sig nif i cant changes in the num ber of foci are ob served
only at 24 h posttreatment (p < 0.05), fig. 4(b).
DIS CUS SION
In  con tem po rary  med i cal  prac tice,  ra di a tion  is
be ing used as an ef fec tive mo dal ity in can cer treat ment 
with the ul  ti  mate goal of pro  vid  ing the most op  ti  mal
ther  a  peu  tic ef  fect. Over the past years, the main chal  -
lenges in can  cer cure were fo  cused on treat  ment and
de  liv  ery plan  ning, with the aim of im  prov  ing the ther  -
a peu tic  ef fects  and  min i miz ing  cor re spond ing,  un in -
tended,  side  ef fects.  How ever,  ra di a tion  on col ogy  is
faced with dose tol  er  ance lim  i  ta  tions and, if it is to
prog ress fur ther and de liver better clin i cal out comes, it 
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Ta  ble 1. Sur  vival pa  ram  e  ters, RBE and SER val  ues for CRL-5876 cells
Treatment a [Gy
–1] b [Gy
–2] SF2 RBE [2 Gy, g] D10 [Gy] SER [D10]
g-rays 0.166 ± 0.059 0.042 ± 0.019 0.61 ± 0.01 1.00 5.6 ± 0.6 1
g-rays + erlotinib 0.789 ± 0.110 – 0.21 ± 0.01 3.12 ± 0.44 2.9 ± 0.4 1.9 ± 0.33
Data are pre  sented as mean ± SEM
Fig  ure 2. Vi  a  bil  ity of CRL-5876 cells af  ter sin  gle and
com bined  treat ments  with  g-rays and erlotinib
de  ter  mined by SRB 72 h (a) and 7 days (b) af  ter
ir  ra  di  a  tion. Ir  ra  di  a  tion doses are 1, 2, 4, 6, and 8 Gy,
while the con  cen  tra  tion of erlotinib (E) is 2 µM. Data
ob  tained from 3 ex  per  i  ments are pre  sented as mean ±
SEM
(* – sin  gle or com  bined treat  ment vs. con  trol, † – com  bined
treat ment vs. g-ir ra di a tion, # – com bined treat ment vs. sin gle 
drug treat ment; 0.01 < p < 0.05 (*, †, #), 0.001 < p < 0.01 (**, 
††, ##), p < 0.001 (***, †††, ###))needs to in te grate bi o log i cal in no va tions into the ra di -
a  tion ther  apy [30]. Mo  lec  u  lar tar  geted drugs as mod  -
ern radiosensitizing agents re  ceive much at  ten  tion.
Pre clin i cal  in vi  tro and in vivo model sys  tems may be
used  to  ex am ine  mech a nisms  un der ly ing  tu mor
radiosensitization by these drugs [31]. The block  ade
of the wild-type EGFR has also been dem  on  strated to
re duce  ra di a tion  re sis tance  through  three  sep a rate
mech a nisms:  by  re duc ing  DNA  re pair,  by  in hib it ing
antiapoptotic  path ways  and  by  re duc ing  pro lif er a tion
[16]. This study de  scribes the abil  ity of the EGFR ty  -
ro sine kinase in  hib i tor, erlotinib, to mod u late the ra di -
a  tion re  sponse in hu  man CRL-5876 NSCLC
adenocarcinoma cells.
Sev eral  pre clin i cal  and  clin i cal  stud ies  are  un -
der  way to eval  u  ate the com  bi  na  tion of erlotinib with
ra  dio  ther  apy [20, 32]. Since there is a lack of ba  sic re  -
search in this field, re  cent in vi  tro stud  ies have been
de  signed with erlotinib given be  fore and/or af  ter ra  di  -
a tion,  but  the  op ti mal  way  of  ad min is ter ing  these
agents needs yet to be es  tab  lished [33]. In this ex  per  i  -
men  tal setup, erlotinib was added 1 h be  fore ir  ra  di  a  -
tion, with pro longed in cu ba tion af ter ir ra di a tion when
the  as says  were  per formed.  A  sim i lar  ex per i men tal
setup was re  ported by Wang and co  work  ers [23].
The bi  o  log  i  cal end  points used in this work, i. e.,
clonogenic sur  vival for the as  sess  ment of ra  di  a  tion
dam  age and colorimetric as  says en  abling the fol  low
up of cel lu lar vi a bil ity af ter ad min is tra tion of dif fer ent
antitumour agents, were cho  sen to al  low for the com  -
ple men tary  anal y ses  of  the  com bined  treat ment  that
was ap plied. All as says were per formed at ap pro pri ate
time  points,  thus  en abling  com par a tive  in ves ti ga tion
of ob  tained data. In ad  di  tion, the ki  netic study of ap  -
pear ance  and  dis ap pear ance  of  g-H2AX foci, par  tic  u  -
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Fig ure 3. Pro lif er a tion of CRL-5876 cells af ter sin gle and 
com bined  treat ments  with  g-rays and erlotinib re  vealed
by BrdU 72 h (a) and 7 days (b) af  ter ir  ra  di  a  tion.
Ir  ra  di  a  tion doses are 1, 2, 4, 6, and 8 Gy, while the
con  cen  tra  tion of erlotinib (E) is 2 µM. Data ob  tained
from 3 ex  per  i  ments are pre  sented as mean ± SEM
(* – sin  gle or com  bined treat  ment vs. con  trol, † – com  bined
treat ment vs. g-ir ra di a tion, # – com bined treat ment vs. sin gle
drug treat ment; 0.01 < p < 0.05 (*, †, #), 0.001 < p < 0.01 (**,
††, ##), p < 0.001 (***, †††, ###)
Fig ure 4. (a) Dis tinc tive mi cro graphs of the cells con tain -
ing g-H2AX foci af  ter sin  gle and com  bined treat  ments
with g-rays and erlotinib, ob  tained by con  fo  cal la  ser
scan ning  mi cro scope  in  or der  to  re veal  ki net ics  of
g-H2AX  foci;  (b)  Ki net ics  of  ir ra di a tion-in duced
g-H2AX foci for  ma  tion af  ter sin  gle and com  bined treat  -
ments with g-rays and erlotinib. g-H2AX foci are de  ter  -
mined at the time points of 0.5, 2, 6, and 24 h. The
ir  ra  di  a  tion dose is 0.1 Gy while the con  cen  tra  tion of
erlotinib is 2 µM. Con  cen  tra  tion of DMSO cor  re  spond  -
ing to that added with erlotinib so  lu  tionlarly ex  tended to the time point of 24 h, was aimed to
cor re late the loss of clonogenic abil ity de tected by CA, 
with the re  ten  tion of DNA dam  age-in  duced foci,
there fore  pro vid ing  a  com ple men tary  ap proach  [22].
As dem  on  strated by CA, with SF2 be  ing 0.61,
the CRL-5876 cells can be con  sid  ered as
radioresistant, fig. 1(a). In com  bined treat  ment,
erlotinib in  creased the radiosensitivity of CRL-5876
cells, reach  ing 0.21 for SF2, whereas the D10 value
also changed from 5.6 to 2.9 Gy, thus giv  ing a SER of
1.9 (tab. 1). The de  crease in col  ony num  ber was ac  -
com  pa  nied by a de  crease in col  ony size, fig. 1(b). A
sim  i  lar con  duct of radiosensitivity as a func  tion of
dose af  ter treat  ments with g-rays alone and in com  bi  -
na  tion with erlotinib was ob  served when cells were
an  a  lyzed by other vi  a  bil  ity tests, such as SRB and
BrdU, figs. 2 and 3. Nev er the  less, CA showed a stron  -
ger in  ac  ti  va  tion of CRL-5876 cells than SRB and
BrdU as says. This can be ex plained by the fact that the
clonogenic as  say mea  sures only the ca  pac  ity of in  di  -
vid  ual cells to form mac  ro  scopic col  o  nies, whilst vi  a  -
bil  ity as  says mea  sure the to  tal pro  tein con  tent (SRB
as  say) or DNA rep  li  ca  tion (BrdU as  say). More  over,
re  cent data in  di  cate that ra  di  a  tion and erlotinib can
cause growth ar  rest by in  duc  ing ac  cel  er  ated cell se  -
nes cence  [23].  Se nes cent  cells  re main  met a bol i cally
ac  tive for an ex  tended time (up to 7 days af  ter treat  -
ment) and there  fore would be scored as “sur  vi  vors” in
vi a bil ity  as says  [34].
Most of the can  cer ther  a  peu  tic agents, in  clud  ing
ra di a tion  ther apy,  di rectly  or  in di rectly  in duce  DNA
dou  ble-strand breaks (DSB). If not prop  erly re  paired
by the cel lu lar re pair ma chin ery, these in ju ries are con -
sid  ered le  thal. One of the first cel  lu  lar re  sponses to
these dam  ages is phosphorylation of histone H2AX,
re  sult  ing in the for  ma  tion of dis  tinct foci within min  -
utes af  ter the ini  tial dam  age [35]. Due to its ca  pa  bil  ity
to  dis tin guish  mi cro scop i cally  vis i ble  foci  in  sin gle
cells,  g-H2AX as  say is widely ap  plied in mon  i  tor  ing
the ef fec tive ness of ra di a tion sensitizers [36]. Ex ploit -
ing the high sen  si  tiv  ity of this as  say, the im  pact of
erlotinib  on  DSB  re pair  ki net ics  af ter  ra di a tion  was
tested. To avoid foci over  lap  ping and, thus, the pos  si  -
ble un  der  es  ti  ma  tion of their num  ber at high doses, a
low  ir ra di a tion  dose,  i.  e., 0.1 Gy, was cho  sen for the
in  ves  ti  ga  tion of the ex  tent of the radiosensitizing ef  -
fect of erlotinib. The re  sults ob  tained  show a sig  nif  i  -
cantly higher num  ber of foci in erlotinib-pretreated
cells 24 h af  ter ra  di  a  tion. It was pre  vi  ously re  ported
that this re  ten  tion of g-H2AX foci is to be as  so  ci  ated
with the loss of clonogenic po  ten  tial [37]. Sev  eral
stud  ies have shown that re pair-de  fi  cient cell lines pre -
serve more foci when an  a  lyzed 24 h af  ter ir  ra  di  a  tion
[38, 39]. Cells that re  tained unrepaired foci are prob  a  -
bly the cells that are in tended to die. The per cent age of
cells that pre served g-H2AX foci 24 h af  ter ir ra di a tion
was cor  re  lated with the per  cent  age of cells that lost
clonogenicity, thus mak  ing it pos  si  ble to use the frac  -
tion of cells with re sid ual foci as a way to es ti mate sen -
si tiv ity  to  kill ing  by  ion iz ing  ra di a tion  [22,  40].
EGFR is in volved in sev eral crit i cal pro cesses in
DNA re pair that in clude im pact on translocation, tran -
scrip  tion and phosphorylation of key pro  teins and
genes re spon si ble for DNA re pair [41]. There fore, this
mul  ti  ple role of EGFR in the DNA re pair pro cess may
be the cause of the radiosensitization ef  fects of
erlotinib on an  a  lyzed CRL-5876 cells. The mo  lec  u  lar
mech  a  nisms by which erlotinib reg  u  lates DSB re  pair
need  fur ther  in-depth  in ves ti ga tion.
CON CLU SION
In sum  mary, re  sults re  veal that g-rays  in ac ti vate
CRL-5876 cells in a dose-de  pend  ent way. Pre  treat  -
ment with erlotinib sen  si  tizes the cells to g-rays, thus
mak  ing this agent valu  able in can  cer treat  ment when
used in syn ergy with ra di a tion. The in situ de tec tion of
g-H2AX foci was used in mon i tor ing the ef fec tive ness
of pre  treat  ment with the ra  di  a  tion sensitizer. The es  ti  -
ma  tion of an op  ti  mal ther  a  peu  tic sched  ule for the ad  -
min is tra tion  of  erlotinib  syn chro nized  with  ra di a tion
treat  ment would be ben  e  fi  cial for a com  bined ther  apy
ap proach.
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RADIOSENZIBILIZACIJA  NESITNO]ELIJSKOG
KARCINOMA  PLU]A  ^OVEKA  INHIBICIJOM  EGFR-a
Molekularno ciqana terapija kancera je va`an pristup za le~ewe ove bolesti. Imaju}i u 
vidu ulogu koju re  cep  tor za epidermalni faktor rasta ima na proliferaciju i pre`ivqavawe
}elija, postoje naznake da ciqani agensi, kao {to su inhibitori tirozin kinaza, npr. erlotinib,
mogu da pove}aju efikasnost zra~ewa u eliminaciji tumora. Ciq ove studije je analiza efekata
razli~itih doza gama zra~ewa kao i testirawe mogu}nosti erlotiniba da pove}a radioosetqivost
}elija humanog adenokarcinoma plu}a u in vi tro uslovima. Primewene su doze gama zra~ewa od 1 Gy do 
8 Gy. U nameri da se pove}a radioosetqivost CRL-5876 adenokarcinoma plu}a, }elije su tretirane
klini~ki relevantnom dozom erlotiniba od 2 mM. Efekti pojedina~nih i kombinovanih tretmana
su pra}eni pomo}u klonogenog pre`ivqavawa }elija, kao i wihove vijabilnosti i proliferacije u
razli~itim vremenskim ta~kama. Za detekciju i vizuelizaciju fosforilisanog histona H2AX
(g-H2AX), koji je va`an biomarker za pra}ewe stvarawa dvolan~anih prekida DNK, kori{}ena je
metoda fluorescentne imunocitohemije. Odgovor na tretmane je pra}en u ~etiri vremenske ta~ke:
30 minuta, 2, 6 i 24 ~asa. Ozra~ivawe gama zracima dovelo je do zna~ajne inaktivacije }elija na
nivou svih pra}enih biolo{kih parametara. Kombinovani tretmani su pokazali konzistentnu
}elijsku inaktivaciju. Tako|e, pove}an broj g-H2AX jedaraca je prime}en nakon pretretmana
erlotinibom u pore|ewu sa samim gama zra~ewem. Ovo ukazuje na pove}awe radioosetqivosti
}elija do koje je do{lo usled naru{ene DNK reparacije.
Kqu~ne re~i: }elija adenokarcinoma plu}a ~oveka, gama zra~ewe, DNK o{te}ewe, erlotinib,
.........................radiosenzibilizacija